Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the world health organization international standard is predictive of CMV disease resolution in transplant recipients

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1546-1553

  Razonable, Raymund R ^a   Åsberg, Anders ^b   Rollag, Halvor ^c   Duncan, John ^d   Boisvert, Denis ^d   Yao, Joseph D ^e   Caliendo, Angela M ^f   Humar, Atul ^g   Do, Tri D ^d  

^a William J von Liebig Transplant Center   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Roche Molecular Diagnostics   (United States)

^e MAYO CLINIC   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

Author keywords

CMV antiviral therapy; CMV DNA test; cytomegalovirus; valganciclovir; World Health Organization international standard

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; VALGANCICLOVIR; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CALIBRATION; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS DNA TEST; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSTICS; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROLOGY; VIROLOGY; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

CMV ANTIVIRAL THERAPY; CMV DNA TEST; CYTOMEGALOVIRUS; VALGANCICLOVIR; WORLD HEALTH ORGANIZATION INTERNATIONAL STANDARD;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; GANCICLOVIR; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 84877274937     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit096     Document Type: Article

References (15)

1. Keay S, Petersen E, Icenogle T, et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Rev Infect Dis 1988; 10(suppl 3):S563-72.
2. Dunn DL, Mayoral JL, Gillingham KJ, et al. Treatment of invasive cy-tomegalovirus disease in solid organ transplant patients with ganciclo-vir. Transplantation 1991; 51:98-106.
3. Dunn DL, Gillingham KJ, Kramer MA, et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994; 57:876-84.
4. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89:779-95.
5. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7:2106-13.
6. Razonable RR, Brown RA, Wilson J, et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 2002; 73:968-73.
7. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186:829-33.
8. Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomeg-alovirus disease in liver transplant recipients. Transplantation 1999; 68:1305-11.
9. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cyto-megalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181:717-20.
10. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation final report. Am J Transplant 2005; 5:218-27.
11. Hayden RT, Yan X, Wick MT, et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a mul-tivariate analysis. J Clin Microbiol 2012; 50:337-45.
12. Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cy-tomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis 2012; 54:1793-7.
13. COBAS® AmpliPrep/COBAS® TaqMan® CMV Test. Package insert. Branchburg, NJ: Roche Molecular; 2012.
14. Hirsch HH, Lautenschlager I, Pinsky BA, et al. An international mul-ticenter performance analysis of cytomegalovirus load tests. Clin Infect Dis 2013; 56:367-73.
15. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032-6.